Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
ATP11B siRNA
- Development stage
- Preclinical
- Lead developer
- University of Texas MD Anderson Cancer Center
- Modality
- Chemically Modified siRNA → Small Interfering RNA (siRNA) → Small RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics, Conjugated siRNA → Small Interfering RNA (siRNA) → Small RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics
- Administration
- Intraperitoneal (in Animal Studies, Via Nanoliposome Delivery)[3]
01
Overview
ATP11B siRNA is a small interfering RNA (siRNA) molecule designed to silence the expression of the ATP11B gene, which encodes a P-type ATPase membrane protein implicated in mediating cisplatin resistance in ovarian cancer. By targeting and degrading ATP11B mRNA, ATP11B siRNA downregulates its expression, sensitizing cancer cells to platinum-based chemotherapy. Preclinical data demonstrate that ATP11B siRNA, usually delivered via nanoliposomes, restores cisplatin sensitivity in resistant ovarian tumors and reduces tumor growth in mouse models. This therapeutic concept is being explored primarily in the context of platinum-resistant ovarian cancer, but the principle of gene silencing via siRNA is applicable to other diseases where ATP11B is implicated[1][3].
- Other names
- ATP11B-targeted siRNAATP-11B-targeted siRNAATP 11B-targeted siRNAsmall interfering RNA against ATP11B
02
Targets
ATP11B (ATPase phospholipid transporting 11B)
Beyond the preview
Go deeper on ATP11B siRNA.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on ATP11B siRNA.